TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07285005: A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

Sponsor: Kaken Pharmaceutical · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,987,288

Rescue Site Savings

+$3,960,096

Unlock Full NCT07285005 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07285005 Rescue Dossier →